Stay updated on PEMBRACA: Pembrolizumab+Carboplatin in Breast Cancer Antigens Clinical Trial
Sign up to get notified when there's something new on the PEMBRACA: Pembrolizumab+Carboplatin in Breast Cancer Antigens Clinical Trial page.

Latest updates to the PEMBRACA: Pembrolizumab+Carboplatin in Breast Cancer Antigens Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedRevision: v3.4.2 is now displayed, replacing Revision: v3.4.1, and a government funding status notice was removed with no changes to the trial details or eligibility criteria. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check21 days agoChange DetectedSite-wide notices about funding status and a revision update (Revision: v3.4.1, replacing v3.4.0) were added; these do not modify study data, eligibility criteria, or other core information. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check28 days agoChange DetectedAdded a glossary display option, a new QC-related label (Last Update Submitted that Met QC Criteria), and a new revision tag (Revision: v3.4.0). Removed the previous QC label variant (Last Update Submitted that met QC Criteria), removed the No FEAR Act data label as a separate item, and adjusted capitalization for No FEAR Act Data and the older revision tag (Revision: v3.3.4).SummaryDifference0.3%

- Check42 days agoChange DetectedRevision: v3.3.4 has been added and replaces the previous revision, v3.3.3. This is an administrative update and does not alter study data or the information shown about the trial.SummaryDifference0.1%

- Check63 days agoChange DetectedFooter now displays 'Revision: v3.3.3'. The strings 'HHS Vulnerability Disclosure' and 'Revision: v3.3.2' are no longer present.SummaryDifference0.1%

- Check92 days agoChange DetectedRevision updated from v3.2.0 to v3.3.2 with no observable changes to study content or layout; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to PEMBRACA: Pembrolizumab+Carboplatin in Breast Cancer Antigens Clinical Trial
Enter your email address, and we'll notify you when there's something new on the PEMBRACA: Pembrolizumab+Carboplatin in Breast Cancer Antigens Clinical Trial page.